DOI: 10.5061/dryad.qrfj6q5fq
title: Data from: A retrospective analysis of infection and antimicrobial resistance patterns of Mycoplasma genitalium among pregnant women in the southwestern United States

description: Background: Mycoplasma genitalium is a sexually transmitted infection
 pathogen. There have been no published studies concerning symptomatology,
 prevalence data, antibiotic resistance profiling or reports of
 co-infection with other STIs in pregnant women. Objective: To describe
 these characteristics among pregnant women attending prenatal clinics in a
 large tertiary care center. Design: Remnant genital samples collected from
 pregnant women between August 2018 and November 2019 were tested for M.
 genitalium and Trichomonas vaginalis by the transcription-mediated
 amplification technique. Specimens with detectable M. genitalium RNA were
 sequenced for 23S rRNA mutations associated with azithromycin resistance
 and parC and gyrA mutations associated with resistance to moxifloxacin.
 Demographic, obstetric and STI co-infection data were recorded. Results:
 Of the 719 samples, 41 (5.7 %) were positive for M. genitalium. M.
 genitalium infection was associated with Black race, Hispanic ethnicity
 and young age (p= .003, .008 and .004 respectively). M. genitalium
 infection was also associated with T. vaginalis co-infection and
 Streptococcus agalactiae (GBS) colonization (p =&lt;0.001 and .002
 respectively). Of the 41 positive samples, 26 (63.4%) underwent successful
 sequencing. Eight (30.8%) had 23S rRNA mutations related to azithromycin
 resistance. One of 26 (3.8%) positive samples with sequencing results had
 the gyrA gene mutation and 1 of 18 sequenced samples (5.6%) had the parC
 gene mutation associated with moxifloxacin resistance. Conclusions:
 Prevalence rates of M. genitalium in pregnant women was 5.7%. M.
 genitalium infection disproportionately affects young Black women
 co-infected with T. vaginalis. Pregnant women remain at risk for
 persistent infection with M. genitalium due to decreased azithromycin
 susceptibility.
description: After Institutional Review Board approval from the Baylor College
 of Medicine, all remnant Aptima Multitest clinician-collected endocervical
 samples from pregnant women presenting to care between August 30, 2018 and
 November 30, 2019 were placed in the Aptima swab specimen transport tube,
 stored for up to 30 days and shipped monthly by overnight mail to
 Marquette University, Milwaukee, WI for <i>M. genitalium</i>
 16S rRNA and <i>Trichomonas vaginalis</i> testing by the
 transcription - mediated amplification technique utilizing Panther System
 automation (Hologic, Inc., San Diego, CA) as previously
 described<sup>11-20.</sup> Only one sample collected at intake
 to care was used for each patient presenting obstetrical care and received
 testing with the Aptima swab for <i>N. gonorrhoeae</i> and
 <i>C. trachamatis </i>per institutional protocol and
 guidelines. <i>M. genitalium</i> positive
 specimens were shipped to the Public Health Agency of Canada, National
 Microbiology Laboratory for additional testing. DNA was extracted from the
 specimens using the MagNA Pure DNA and Viral Nucleic Acid kit (Roche,
 Laval, Quebec) per manufacturer’s instruction. Specimens with detectable
 <i>M. genitalium </i>DNA were subsequently analyzed by
 sequencing the 23S rRNA gene to identify mutations associated with
 azithromycin resistance and <i>parC</i> and <i>gyrA
 </i>genes associated with resistance to moxifloxacin.
 Demographic variables, obstetrical data, pelvic symptoms
 consistent with cervicitis (pelvic pressure, vaginal discharge, lower
 abdominal cramping), and STI co-infection [<i>Neisseria
 gonorrhoeae</i>, <i>Chlamydia trachomatis, </i>herpes
 simplex virus, human immunodeficiency virus,<i> Trichomonas
 vaginalis</i>, human papillomavirus (types 16,18)] Bacterial
 vaginosis and group <i>B Streptococcus</i> (GBS) colonization
 data were extracted from the chart and recorded by the investigators.
 Patient characteristics, co-infection with other STI and <i>M.
 genitalium </i>resistance profiles were summarized by means with
 standard deviations, or frequencies with percentages.  Fisher's exact
 test or the Wilcoxon Rank Sum test was used to determine differences
 between women positive and negative for <i>M. genitalium
 </i>in demographic, clinical characteristics, and co-infections with
 other STIs.  Exact 95% confidence intervals (CIs) were determined for the
 resistance profiles. STROBE guidelines were followed for the study design,
 methods and analysis<sup>34</sup>. All protected health
 information was removed from discarded samples prior to shipment and all
 data was entered into a de-identified database using only study numbers to
 link information at completion of study.
description: Text in red denotes more collected data since submission.